Tauriga Sciences Inc (TAUG) financial statements (2020 and earlier)

Company profile

Business Address 555 MADISON AVENUE
NEW YORK, NY 10022
State of Incorp. FL
Fiscal Year End March 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000000
Cash and cash equivalents0000000
Receivables000 000
Inventory, net of allowances, customer advances and progress billings0000   
Inventory0000   
Disposal group, including discontinued operation   0   
Other undisclosed current assets0011111
Total current assets:1111111
Noncurrent Assets
Operating lease, right-of-use asset000 
Property, plant and equipment0000000
Total noncurrent assets:0000000
TOTAL ASSETS:1111111
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0000000
Accounts payable0000000
Accrued liabilities000 000
Interest and dividends payable0000000
Deferred revenue  0 
Debt1000000
Disposal group, including discontinued operation   0   
Customer refund liability0  0   
Other undisclosed current liabilities0  0   
Total current liabilities:1000000
Noncurrent Liabilities
Long-term debt and lease obligation000    
Operating lease, liability000 
Other undisclosed noncurrent liabilities    000
Total noncurrent liabilities:000 000
Total liabilities:1000000
Stockholders' equity
Stockholders' equity attributable to parent(0)011001
Common stock0000000
Additional paid in capital57575756555555
Accumulated deficit(58)(57)(56)(55)(55)(54)(54)
Stockholders' equity attributable to noncontrolling interest    (0)(0)(0)
Total stockholders' equity:(0)011001
TOTAL LIABILITIES AND EQUITY:1111111

Income statement (P&L) ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
Revenues0000   
Cost of revenue(0)(0)(0)   (0)
Cost of goods and services sold      (0)
Gross profit:000   (0)
Operating expenses(1)(0)(1)(0)(0)(0)(0)
Other undisclosed operating income (loss) (0) 0  0
Operating loss:(0)(0)(1)(0)(0)(0)(0)
Nonoperating income (expense)(0)(0)0(0)(0)00
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before equity method investments, income taxes:(1)(1)(1)(1)(0)(0)0
Other undisclosed income from continuing operations before income taxes0000   
Income (loss) from continuing operations:(1)(1)(1)(1)(0)(0)0
Other undisclosed loss before gain (loss) on sale of properties   (0)   
Income (loss) before gain (loss) on sale of properties:(1)(1)(1)(1)(0)(0)0
Other undisclosed net income (loss)   (0)0  
Net income (loss):(1)(1)(1)(1)(0)(0)0
Other undisclosed net income attributable to parent     00
Net income (loss) available to common stockholders, diluted:(1)(1)(1)(1)(0)(0)0

Comprehensive Income ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
Net income (loss):(1)(1)(1)(1)(0)(0)0
Other comprehensive income (loss)     0(0)
Comprehensive loss:(1)(1)(1)(1)(0)(0)(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent     (0)0
Comprehensive income (loss), net of tax, attributable to parent:(1)(1)(1)(1)(0)(0)0

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: